:This article aims to assess the clinical data reported by ALX Oncology regarding the use of evorpacept in combination with standard-of-care treatment in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma (R/R B-NHL). The study involved twenty patients with indolent and aggressive R/R B-NHL who received evorpacept in combination with rituximab and lenalidomide (R2). The study findings indicate that this combination therapy was well-tolerated, displaying a safety profile comparable to historical R2 treatment. Furthermore, initial activity results demonstrated a notable best overall response rate (ORR) of 94% and a complete response rate (CRR) of 83% in patients with indolent R/R B-NHL. These findings highlight the potential of evorpacept as an effective treatment option for patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma.
Non-Hodgkin Lymphoma (NHL) represents a heterogeneous group of malignancies originating from lymphoid tissue. Particularly, B-cell Non-Hodgkin Lymphoma (B-NHL) accounts for a significant proportion of NHL cases. Though standard treatments such as rituximab and lenalidomide (R2) have shown some success, the need for novel therapeutic approaches to manage relapsed or refractory B-NHL remains a priority.
:This article discusses the encouraging clinical data reported by ALX Oncology on the use of evorpacept in combination with standard-of-care treatment in patients with relapsed or refractory B-NHL. By interpreting the study findings, this article aims to highlight the potential of evorpacept as a promising treatment option for patients with indolent and aggressive forms of R/R B-NHL.
Methods:The study included twenty patients with indolent (n=18) and aggressive (n=2) R/R B-NHL. All patients received evorpacept in combination with standard rituximab and lenalidomide (R2). The study’s primary endpoints were overall response rate (ORR) and complete response rate (CRR), both of which were assessed in comparison to historical R2 treatment benchmarks.
Results:The combination therapy of evorpacept and R2 demonstrated a notable safety profile, with no significant adverse events reported. Initial activity results were particularly promising, with an impressive ORR of 94% and a CRR of 83% in patients with indolent R/R B-NHL. Moreover, these response rates surpassed the historical R2 treatment benchmark of 34% for CRR.
Conclusion:The clinical data presented by ALX Oncology suggest that the addition of evorpacept to standard-of-care treatment with R2 shows promising potential for managing relapsed or refractory B-cell Non-Hodgkin Lymphoma. These findings highlight the need for further research and clinical trials to explore the efficacy and long-term outcomes of this therapeutic combination. Evorpacept could emerge as an effective treatment option, providing hope for patients with B-NHL who have limited options for disease control.
Keywords: B-cell Non-Hodgkin Lymphoma, relapsed/refractory, evorpacept, rituximab, lenalidomide, combination therapy, overall response rate, complete response rate.
Comments